Reduction of Adverse Drug Events and Readmissions

Conditions

• Pharmacogenomic Testing for Medication Management

Eligibility Criteria

Sex

ALL

Age

25 Years - N/A

Healthy Volunteers

Accepted

Study Details

Pharmocogenomic test assessment in the medication regimen and disease management for patients under drugs known with genetic variation.

Key Dates

Start date

Mar 15, 2019

Status verified

Dec 2023

Primary completion

Mar 31, 2025

Completion

Dec 31, 2026

Study Design

Enrollment

280,000 participants (estimated)

Primary Outcome Measure

Radar, Pharmocogenomic [ Time Frame: The period of enrollment is anticipated to be 36 months with a 120- day follow-up period, for total study duration of approximately 40 months from first patient enrolled to completion of follow-up on the last patient in. ]

Central Contacts

• Diana Messir
  239-908-0412
  [email protected]
• Diana M Messir
  239-908-0412
  [email protected]

Locations (1)

Find similar trials in York, PA